Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure

• Published in: Cardiovascular drugs and therapy Vol. 4; no. 3; p. 705
• Main Authors: Bartels, G L, Remme, W J, Wiesfeld, A C, Kok, F J, Look, M P, Krauss, X H, Kruyssen, H A
• Format: Journal Article
• Language: English
• Published: United States 01.06.1990
• Subjects: Aged; Atrial Function; Blood Pressure - drug effects; Drug Administration Schedule; Female; Heart - physiology; Heart Failure - drug therapy; Heart Failure - physiopathology; Hemodynamics - drug effects; Humans; Male; Middle Aged; Pulmonary Wedge Pressure - drug effects; Quinolines - administration & dosage; Quinolines - pharmacology; Reproducibility of Results; Time Factors; Vasodilator Agents - administration & dosage; Vasodilator Agents - pharmacology
• ISSN: 0920-3206
• DOI: 10.1007/BF01856558

The duration and reproducibility of hemodynamic effects of flosequian, a direct-acting, balanced-type vasodilator, were studied in 19 heart failure patients (NYHA class 3.0 +/- 0.7) receiving 100 mg orally (day 1), placebo (day 2), and again 100 mg (day 3). Flosequinan immediately reduced systemic and pulmonary resistance (23% and 35%, respectively, at 60-90 minutes postdrug) and decreased pulmonary wedge, right atrial, mean pulmonary artery, and mean arterial pressure by 38%, 50%, 25%, and 7%, respectively. Concomitantly, cardiac output, and stroke volume and work increased by 26%, 20%, and 22%, respectively. Most hemodynamic effects persisted for 48 hours. In contrast, changes in pulmonary wedge and arterial pressures, stroke volume, and stroke work only lasted for 2-12 hours. Maximum absolute changes on day 3 were generally comparable with first-dose effects with, again, long-lasting effects on systemic resistance and cardiac output. However, changes in pulmonary artery, wedge, and resistance were significantly shorter than after first dose administration. These data indicate sustained and reproducible arterial dilating effects of flosequinan, but less pronounced and shorter lasting pulmonary arterial and venodilator properties.